ArticleMedicina (Kaunas, Lithuania)2025
Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer.
Ahmet Burak Agaoglu, Atike Pinar Erdogan, Ferhat Ekinci, Mustafa Sahbazlar, Guler Nur Tekustun, Ozgur Tanriverdi, Salih Tunbekici, Erdem Goker, Mehmet Sinan Akarca, Can Cangur and 7 more
Abstract read
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Ahmet Burak AgaogluDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.ORCID 0000-0001-5528-7852 Atike Pinar ErdoganDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.ORCID 0000-0003-4859-7574 Ferhat EkinciDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.ORCID 0000-0002-9317-942X Mustafa SahbazlarDepartment of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey.
Guler Nur TekustunDepartment of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla 48000, Turkey.
Ozgur TanriverdiDepartment of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla 48000, Turkey.ORCID 0000-0002-0598-7284 Salih TunbekiciDepartment of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Turkey.
Erdem GokerDepartment of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Turkey.ORCID 0000-0001-6180-713X Mehmet Sinan AkarcaDepartment of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Turkey.
Can CangurDepartment of Medical Oncology, Faculty of Medicine, Selcuk University, Konya 42075, Turkey.ORCID 0009-0004-1400-0594 Taliha Guclu KantarDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20070, Turkey.
Sedat BiterDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey.ORCID 0000-0002-1053-0668 Ertugrul BayramDepartment of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey.ORCID 0000-0001-8713-7613 Gokhan ColakDepartment of Medical Oncology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin 09100, Turkey.ORCID 0000-0002-3802-461X Bilgin DemirDepartment of Medical Oncology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin 09100, Turkey.ORCID 0000-0003-4380-9419 Hasan BasirDepartment of Medical Oncology, Faculty of Medicine, Mersin University, Mersin 33110, Turkey.
Vehbi ErcolakDepartment of Medical Oncology, Faculty of Medicine, Mersin University, Mersin 33110, Turkey.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Ado-Trastuzumab EmtansineBreast NeoplasmsNeoadjuvant TherapyAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCyclophosphamideDocetaxelDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPaclitaxelAdo-Trastuzumab EmtansineAntibodies, Monoclonal, HumanizedCyclophosphamideDocetaxelDoxorubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPaclitaxelpertuzumabTrastuzumabbreast neoplasmsHER2-positivepost-neoadjuvant treatment outcomesreal-world outcomes
Identifiers
PMID41303803
PMCPMC12654407
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390